molecules of the month

compound 23

oral CAT K inhibitior

reduced uCTX-I levels in dog model

from opt of a previously disclosed cmpd

Bioorg. Med. Chem. Lett.

Merck, West Point, PA

compound 23 chemical structure oral CAT K inhibitior - Merck, West Point, PA
4 mins read

Context. “Compound 23” (Merck) is a selective oral cathepsin K (CatK) inhibitor intended for osteoarthritis.  Osteoarthritis affects around 15% of the population, and current treatments offer only symptom relief, highlighting the need for targeted treatments. Prior to the “compound 23”, several CatK inhibitors had reached clinical development: relacatib (GSK), balicatib (Novartis), ONO-5334 (Ono Pharmaceuticals), and odanacatib (Merck). Merck’s preclinical compound MK-1256 was only 40-fold selective, so they set out to develop a compound with at least 1000-fold selectivity for CatK over other biologically relevant cathepsins, using MK-1256 as a starting point.  Target. CatK is a dimeric collagen-degrading cysteine protease and plays a key role in bone resorption by osteoclasts. Upregulation of the enzyme has been observed in articular cartilage of…

request a trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more.

Interested in learning more? Submit this form to request a trial.

already a member? log in: